A retrospective cohort study using data from patients in 21 countries showed use of semaglutide use was not linked to an ...

Compounded versions of semaglutide, the active ingredient in approved diabetes and obesity drugs Ozempic and Wegovy, have ...

THURSDAY, Nov. 7, 2024 (HealthDay News) -- The head of the company that makes the diabetes and obesity drugs Ozempic and ...

Semaglutide offers a multifaceted approach to type 2 diabetes treatment, enhancing insulin release and reducing blood sugar ...

Once-weekly semaglutide shows significant reduction in knee osteoarthritis pain and body weight in adults with obesity, a ...

Abbott's FreeStyle Libre 2 and 3 are the first and only patient-applied continuous glucose monitoring (CGM) systems to be ...

Novo Nordisk, the maker of Ozempic, reported that compounded versions of semaglutide, the main ingredient in Ozempic and ...

Results demonstrated the mean total medical costs per patient per year decreased significantly after patients began ...

A new study published in the New England Journal of Medicine showed that once-weekly injectable semaglutide led to ...

In the ESSENCE trial, semaglutide improved liver fibrosis in patients with metabolic dysfunction-associated steatohepatitis ...

Novo Nordisk’s CEO has alerted healthcare professionals about the growing risks associated with compounded semaglutide, a ...

Semaglutide shows promise in treating knee osteoarthritis by reducing pain and weight, offering a safe alternative to traditional pharmacological interventions.